



# Lunettes à Hauts débits chez l'adulte

**Arnaud Bruyneel, RN, CCRN, MSc, PhDc  
(ULB)**

Assistant ULB

Vice president SIZ Nursing


Member of council EfCCNa

Nurse ICU, CHU Tivoli

**Virignie Coolens, RN, CCRN**

Nurse ICU, CHU Tivoli

# Introduction



**Fig. 1** High-flow nasal cannula oxygenation (HFNCO) device. An air/oxygen blender, allowing  $FiO_2$  ranging from 0.21 to 1.0, generates flows of up to 60 L/min. The gas is heated and humidified by an active heated humidifier and delivered via a single limb

# Oxygénothérapie



# F&P Optiflow™



**OPTIMAL HUMIDITY**

**DÉBIT**

Clairance mucociliaire

Confort

Apport  
d'oxygène précis

Rinçage de l'espace  
mort anatomique

Faible niveau  
de pression

1


2

3

4


5

# Dilution de la FiO<sub>2</sub>



Adapted from Masclans et al. 2012.

# Précision de la FiO2



Sim et al. Anesthesia 2008

- **Vmin = 20 l/min**
  - O<sub>2</sub> = 15 l/min
  - FiO<sub>2</sub> ≈ 60 %
- **Vmin = 30 l/min**
  - O<sub>2</sub> = 15 l/min
  - FiO<sub>2</sub> ≈ 46 %
- **O<sub>2</sub> = 50 l/min**
  - FiO<sub>2</sub> ≈ 100 %


Mauri et al. Am J Resp Crit Care Med 2017

# Dilution de la FiO<sub>2</sub>

Reliability of methods to estimate the fraction of inspired oxygen in patients with acute respiratory failure breathing through non-rebreather reservoir bag oxygen mask

Rémi Coudroy,<sup>1,2</sup> Jean-Pierre Frat,<sup>1,2</sup> Christophe Girault,<sup>3,4</sup> Arnaud W Thille<sup>1,2</sup>


SI  
Nurs



# Réglages - taille canules

**Optiflow™ Nasal Cannula**


- OPT842E (small)  
1 month
- OPT844E (medium)  
1 month
- OPT846E (large)  
1 month




The image shows three different sizes of Optiflow nasal cannulas: small, medium, and large. Each size is accompanied by a photograph of the device. To the right, a diagram illustrates a person's head and neck with a nasal cannula inserted into the nostrils, connected to a tube.



# Réglages – température



# Réglages - débit





## Réglages - débit

<b>FiO2</b>	<b>21-30%</b>	<b>30-40%</b>	<b>40-60%</b>	<b>60-100%</b>
<b>Débit</b>	<b>30 l/min</b>	<b>30-40 l/min</b>	<b>40-50 l/min</b>	<b>50-70 l/min</b>

NURSIR 19

# Oxygen therapy for acutely ill medical patients: a clinical practice guideline

BMJ 2018 ; 363 doi: <https://doi.org/10.1136/bmj.k4169> (Published 24 October 2018)

Cite this as: *BMJ* 2018;363:k4169



## Overview of recommendations


### Recommendation 1 **STRONG**

Stop oxygen therapy no higher than 96% saturation

### Recommendation 2 **WEAK**

We suggest not starting oxygen therapy between 90-92% saturation

Peripheral capillary oxygen saturation (SpO<sub>2</sub>)



**Applies to:**  
Acutely ill adult medical patients (with exceptions)

### Recommendation 3 **STRONG**


Do not start oxygen therapy at or above 93% saturation

**Applies to:**  
Patients with acute stroke or myocardial infarction

	Overall, % (n)	Seniors, % (n)	Juniors, % (n)	p*
Hypoxemic ARF	100 (111/111)	100 (68/68)	100 (43/43)	1
Pneumonia	98 (109/111)	97 (66/68)	100 (43/43)	0.52
Thoracic trauma	91 (100/110)	90 (60/67)	93 (40/43)	0.74
Pulmonary embolism	85 (94/110)	87 (58/67)	84 (36/43)	0.78
ARDS	71 (78/110)	67 (45/67)	77 (33/43)	0.39
Acute pulmonary edema	57 (63/111)	74 (50/68)	30 (13/43)	< 0.0001
Acute severe asthma	40 (44/109)	45 (30/67)	33 (14/42)	0.32
"Do not intubate" patients	92 (100/109)	90 (60/67)	95 (40/42)	0.48
Per bronchoscopy	92 (97/106)	91 (58/64)	93 (39/42)	1
Preoxygenation before ETI	84 (86/102)	81 (51/63)	90 (35/39)	0.28
Post-operative ARF	76 (80/105)	77 (50/65)	75 (30/40)	0.82
Post-extubation ARF treatment	70 (74/105)	70 (45/64)	71 (29/41)	1
Post-extubation ARF prevention	44 (39/89)	45 (25/56)	42 (14/33)	1
Hypercapnic ARF	33 (27/83)	29 (15/52)	39 (12/31)	0.47
Bronchial dilatation	32 (35/108)	27 (18/67)	41 (17/41)	0.14
Thoracic wall deformity	32 (35/111)	30 (19/68)	37 (16/43)	0.40
COPD exacerbation	28 (31/110)	22 (15/67)	37 (16/43)	0.13
Acute pulmonary edema	25 (28/111)	31 (21/68)	16 (7/43)	0.12
Neuromuscular disease	20 (22/111)	19 (13/68)	21 (9/43)	0.81
Obesity hypoventilation syndrome	19 (21/111)	16 (11/68)	23 (10/43)	0.46
Acute severe asthma	14 (15/111)	15 (10/68)	12 (5/43)	0.78
Obstructive sleep apnea syndrome	7 (8/110)	6 (4/67)	9 (4/43)	0.71

ARF: Acute respiratory failure; ARDS: Acute respiratory distress syndrome; COPD: chronic obstructive pulmonary disease; ETI: endotracheal intubation. HFNC: high-flow nasal cannula; ICU: intensive care unit


\*Comparisons were performed between junior and senior ICU physicians




**No. at Risk**

High-flow oxygen	106	100	97	94	94	93	93
Standard oxygen	94	84	81	77	74	73	72
Noninvasive ventilation	110	93	86	80	79	78	77

**Figure 3.** Kaplan–Meier Plot of the Probability of Survival from Randomization to Day 90.

**B**

# LHD hors USI ...



Published: October 05, 2020 DOI:<https://doi.org/10.1016/j.eclinm.2020.100570>

$$\frac{\text{SpO}_2 / \text{FiO}_2}{\text{Respiratory Rate}} = \text{ROX index}$$

**Example at 6 hours**

---

SpO<sub>2</sub> = **88%**

---

FiO<sub>2</sub> = **.70**

---

RR = **28** breaths/minute


$$\frac{88 / .70}{28} = 4.48$$

In the example above, the resulting score of **4.48** is greater than the score for predicted failure at 6 hours (**3.47** as shown in the ROX Score table right). Therefore, continued NHF treatment should be considered.

ROX score margin for failure over time

Time Point (Hours of NHF use)	ROX Score	Positive Predictive Value %
2 hours	< 2.85	98
<b>6 hours</b>	<b>&lt; 3.47</b>	98-99
12 hours	< 3.85	99
> 12 hours	< 4.88	80


cumulative incidence of intubation



Cumulative number of events

All	0	31	33	37	37	38	39	39	39
ROXH0H4<5.37	0	13	14	17	17	18	18	18	18
ROXH0H4>5.37	0	2	3	4	4	4	5	5	5

(b)



Cut-point	Sensitivity	Specificity	PPV	NPV
3.7	90%	37%	56%	81%
2.7	68%	77%	72%	73%
2.2	33%	90%	74%	60%

**TABLE 1**

Summary of exhaled smoke dispersion distances with different oxygen devices

Oxygen device	Flow rate L·min <sup>-1</sup>	Dispersion distance cm	Ref.
HFNC	60	17.2±3.3	[6]
	30	13.0±1.1	[6]
	10	6.5±1.5	[6]
Simple mask	15	11.2±0.7	[7]
	10	9.5±0.6	[7]
Non-rebreathing mask	10	24.6±2.2	[7]
Venturi mask at $F_{IO_2}$ 0.4	6	39.7±1.6	[7]
Venturi mask at $F_{IO_2}$ 0.35	6	27.2±1.1	[7]


Summary of studies evaluating oxygen delivery devices using a high-fidelity human simulator with smoke particles of <1 µm (an aerosol of solid particles). The smoke was illuminated by a laser light-sheet and high-definition video was used to measure dispersion distance away from the manikin. Indicated dispersion distances give an idea of proximity of contaminated bio-aerosols, to which healthcare workers may be directly exposed. **HFNC**: high-flow nasal cannula;  $F_{IO_2}$ : inspiratory oxygen fraction.



## Preliminary Findings on Control of Dispersion of Aerosols and Droplets During High-Velocity Nasal Insufflation Therapy Using a Simple Surgical Mask

### Implications for the High-Flow Nasal Cannula

Figure 1 – Velocity map of gas flow for all tested settings. HVNI 1/4 high-velocity nasal insufflation.




RESEARCH

Open Access



# Surgical mask on top of high-flow nasal cannula improves oxygenation in critically ill COVID-19 patients with hypoxemic respiratory failure

Virginie Montiel<sup>1\*</sup>, Arnaud Robert<sup>1</sup>, Annie Robert<sup>2</sup>, Anas Nabaoui<sup>1</sup>, Tourneux Marie<sup>1</sup>, Natalia Morales Mestre<sup>1,3</sup>, Maerckx Guillaume<sup>1,3</sup>, Pierre-François Laterre<sup>1</sup> and Xavier Wittebole<sup>1</sup>




# The Double-Trunk Mask Improves Oxygenation During High-Flow Nasal Cannula Therapy for Acute Hypoxemic Respiratory Failure

Respiratory Care April 2019

Frédéric Duprez, Arnaud Bruyneel, Shahram Machayekhi, Marie Droguet, Yves Bouckaert, Serge Brimiouille, Gregory Cuvelier, and Gregory Reychler



Fig. 1. Subject receiving classic high-flow nasal cannula (HFNC) therapy with a double-trunk mask (DTM). The DTM is composed of a normal aerosol mask (nebulizer and mouth piece) with 2 lateral holes (22 mm in diameter) and 15 cm of corrugated tubing inserted in the holes. The DTM was only applied to the face of subjects breathing spontaneously without obstructed airways. Subjects were already receiving O<sub>2</sub> via a nasal cannula. 1: trunk; 2: HFNC; 3: nebulizer; 4: aerosol mask. The nasal cannula is positioned according to the manufacturer's recommendation.





En pratique ...

[https://vimeo.com/476170424/9c4e36b65f?fbclid=IwAR3u2P5tsNVbuyMk2i3TOXsfDYH-HY3-2\\_Gi58m4cWUSpldViynQ8iZ72Zw](https://vimeo.com/476170424/9c4e36b65f?fbclid=IwAR3u2P5tsNVbuyMk2i3TOXsfDYH-HY3-2_Gi58m4cWUSpldViynQ8iZ72Zw)

SIZ

Nursing

